Drug shortages in Israel: regulatory perspectives, challenges and solutions
Open accessAbstract
BACKGROUND: Pharmaceutical drug shortages (DSs) are a global problem which presents challenges to countries around the world. Shortages of pharmaceutical products may have a direct detrimental impact on public health and patients' wellbeing by causing delayed, or even lack of, treatment. Moreover, DSs may force both patients and caregivers to use unfamiliar drugs, which could lead to medication errors. The objective of our study was to analyze DSs in Israel during the years 2013-2015, assessing their etiology and exploring the steps taken for their mitigation and prevention. METHODS: The database of the Israeli Ministry of Health (MoH) on drug shortages contains all the DSs recorded in Israel since 2013, detailing the cause of the DS, its duration, steps taken in its' management and the availability of generic or therapeutic alternatives. Selected examples of DSs from the database are described in this paper in order to identify the causes of DSs, the scope of the problem and possible solutions. Additionally, we have reviewed the recent activities performed by European Medicine Agency (EMA) and the American Food and Drug Administration (FDA) in their efforts to minimize this problem. RESULTS: Several factors contributing towards DSs in Israel were identified, including quality problems in both the final drug product and in the raw materials, upgrades and improvements of the manufacturing process required by the MoH, manufacturing by a sole supplier, dramatic price decrease in off-patent medications causing the manufacturer to discontinue the distribution of the product in Israel, just-in-time inventory control, and others. One of the most important steps in managing drug shortages was identified to be early notification of the shortage by the Marketing Authorization Holder (MAH) to the MoH. In 2013, the Israeli MoH updated the regulation on drug shortages instructing MAHs on their obligation of early notification to the MoH. Furthermore, various steps dealing with marketing withdrawal of drugs and temporary drug shortages are being implemented in Israel, such as suspending any further reductions in drug prices below 17 new Israeli shekels, instructing all MAHs to maintain no less than 1 month supply of all registered and non-registered drugs in Israel and allowing an expedited registration pathway for well-established use/grandfather drugs. CONCLUSIONS: Drug shortages pose significant public health hazards worldwide. Early notification to the MoH and open dialog with MAHs are essential for managing DSs and mitigating their impact. Despite the efforts carried out by health regulatory authorities worldwide, DSs still pose a significant threat to public health.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Shortage of APIs affects many manufacturers worldwide, causing medicine shortages and leading to concerns with patient management.
“Shortage of APIs affects many manufacturers worldwide, causing medicine shortages and leading to concerns with patient management [5, 43, 44].”
From Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Impact of drug shortages on U.S. health systems.
Kaakeh, R., Sweet, B. V., Reilly, C., Bush, C. G., DeLoach, S. L., Higgins, B., Clark, A. M., & Stevenson, J. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110210 · Cited by 230 · cited 1× · see citing works
“Another $216 million of indirect costs were estimated as a result of labor costs due to time spent by healthcare personnel in the management of DSs in hospitals [9, 13].”
BackgroundEconomic and Technological Drivers of Generic Sterile Injectable Drug Shortages
Woodcock, J., & Wosinska, M. (2012) · Clinical pharmacology and therapy · doi:10.1038/clpt.2012.220 · Cited by 173 · cited 1× · see citing works
“Failure of quality management in facilities that produce the finished dosage form of the drug was directly responsible for 56% of sterile injectable DSs in 2011 in the US [17].”
BackgroundEffects on Patient Care Caused by Drug Shortages: A Survey
McLaughlin, M. M., Kotis, D., Thomson, K., Harrison, M., Fennessy, G., Postelnick, M., & Scheetz, M. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.9.783 · Cited by 143 · cited 1× · see citing works
“cellations included procedures, surgeries, chemotherapy and other treatments [10].”
BackgroundImpact of Drug Shortages on Health System Pharmacies in the Southeastern United States
Caulder, C. R., Mehta, B., Bookstaver, P., Sims, L. D., & Stevenson, B. (2015) · Hospital Pharmacy · doi:10.1310/hpj5004-279 · Cited by 65 · cited 2× · see citing works
“tors in North Carolina, South Carolina, Georgia, and Florida [11].”
BackgroundThe Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety.
Nonzee, N., & Luu, T. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-43896-2_6 · Cited by 32 · cited 2×
“A recent paper by CL Ventola, emphasized the consequent mortality associated with DSs in the US [9].”
BackgroundHughes, K., Goswami, E., & Morris, J. L. (2015) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-20.6.453 · Cited by 28 · cited 1×
“The authors hypothesize that the reason for this lack of difference is ongoing communication and information provided by the clinical pharmacists and routine face-to-face education with prescribers during the shortage period [12].”
BackgroundCompetition Issues in the Distribution of Pharmaceuticals
Kanavos, P., & Wouters, O. (2014) · OECD Competition Law and Policy Working Papers · doi:10.1787/9d2d4150-en · Cited by 26
Shortage of streptomycin: time for a change of approach?
Lancet, T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62116-2 · Cited by 9 · see citing works
Flagged first, then by citations
10 of the 18 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- [8]Global approaches to addressing shortages of essential medicines in health systems. In: Medicines shortages. WHO Drug Inf. 2016;30:2. http://apps.who.int/medicinedocs/documents/s22463en/s22463en.pdf. Accessed 14 July 2016.
- [9]Ventola CL The drug shortage crisis in the United States P T 2011 36 11 749 757 PMC3278171 22346307
Cited by
Sorted by citations
Drug Shortage: Causes, Impact, and Mitigation Strategies
Shukar, S., Zahoor, F., Hayat, K., Saeed, A., Gillani, A., Omer, S., Hu, S.-C., Babar, Z., Fang, Y., & Yang, C.-J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.693426 · Cited by 301 · see citing works
“Communication among regulatory authorities and stakeholders at the national and international level is critical in administering drug shortages (Costelloe et al., 2015; Schwartzberg et al., 2017; Walker et al., 2017).”
BackgroundInfluentialMedicine Shortages: Gaps Between Countries and Global Perspectives
Acosta, A., Vanegas, E. P., Rovira, J., Godman, B., & Bochenek, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00763 · Cited by 147 · see citing works
Modisakeng, C., Matlala, M., Godman, B., & Meyer, J. C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05080-1 · Cited by 130 · see citing works
“Shortage of APIs affects many manufacturers worldwide, causing medicine shortages and leading to concerns with patient management [5, 43, 44].”
BackgroundComprehensive analysis of oncogenic determinants across tumor types via multi-omics integration
Ubaid, S., Kushwaha, R., Kashif, M., & Singh, V. K. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.08.010 · Cited by 73 · see citing works
New regulatory strategies to manage medicines shortages in Europe
Musazzi, U. M., Giorgio, D. D., & Minghetti, P. (2020) · International journal of pharmaceutics · doi:10.1016/j.ijpharm.2020.119171 · Cited by 71 · see citing works
“Medicine shortages have risen worldwide, straining the capability of National Healthcare Systems in ensuring patients’ access to pharmacological therapies (Beck et al., 2019; Jia and Zhao, 2017, Schwartzberg et al., 2017).”
BackgroundAtif, M., Malik, I., Mushtaq, I., & Asghar, S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027028 · Cited by 68 · see citing works
Atif, M., Sehar, A., Malik, I., Mushtaq, I., Ahmad, N., & Babar, Z. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06812-7 · Cited by 55 · see citing works
Atif, M., Malik, I., Asif, M., Qamar-uz-Zaman, M., Ahmad, N., & Scahill, S. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819837-7.00024-8 · Cited by 29 · see citing works
Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications
Miljković, N., Godman, B., Kovačević, M., Polidori, P., Tzimis, L., Hoppe‐Tichy, T., Saar, M., Antofie, I., Horváth, L., Rijdt, T. D., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00357 · Cited by 38 · see citing works
“The Israeli Ministry of Health conducts a protocol for healthcare professionals, managers, and importers to carry out risk assessment to propose solutions implemented nationally if no generic alternatives are available (Schwartzberg et al., 2017).”
BackgroundBerman, T. S., Barnett-Itzhaki, Z., Berman, T., & Marom, E. (2023) · Israel Journal of Health Policy Research · doi:10.1186/s13584-023-00562-z · Cited by 32
“This legislation is meant to be a quick and effective way of obtaining drug supply in shortage [89].”
BackgroundRavela, R., Lyles, A., & Airaksinen, M. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08309-3 · Cited by 30
Drug shortages in Canada: Data for 2016-2017 and perspectives on the problem.
Videau, M., Lebel, D., & Bussières, J. (2019) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2018.11.007 · Cited by 23 · see citing works
Shi, Y., Sun, S., Deng, J., Liu, S., Yin, T., Peng, Q., Gong, Z., Cheng, Z., & Zhou, B. (2022) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2022.6360 · Cited by 22 · see citing works
“The inclusion criteria were as follows: (1) more than 10 years of working experience in a medical institution (clinical pharmacy, pharmacy administration, or clinical medicine) or distribution enterprise (drug management), (2) deputy senior or above the position of professional or business administrator, and (3) volun…”
Bilal, A. I., Bititci, U., & Fenta, T. G. (2024) · Pharmacy · doi:10.3390/pharmacy12050132 · Cited by 24 · see citing works
“…wastage of products [25,76,79] Strengthening access to medicines through public-private partnerships [80] Increase communication among stakeholders [34,41,64,67,70,71,74,80,81] Advance notification system when there is shortage [67,74,82] Improving the procurement lead time [74] Restriction and…”
BackgroundBade, C., Olsacher, A., Boehme, P., Truebel, H., & Fehring, L. (2023) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2023.05.007 · Cited by 15 · see citing works
Causes and management of drug shortages: A scoping review
Cornelissen, N., Zielhuis, S. W. J., van den Bemt, P. M. L. A., & van den Bemt, B. J. F. (2025) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2025.10.008 · Cited by 16 · see citing works
Alshibli, F., Alqarni, K. A., & Balfaqih, H. (2024) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2024.101457 · Cited by 14 · see citing works
Zovi, A., Musazzi, U. M., D'Angelo, C., Piacenza, M., Vimercati, S., & Cilurzo, F. (2021) · Journal of Interprofessional Education & Practice · doi:10.1016/j.xjep.2021.100472 · Cited by 11
Akinwumi, A., Olaolorun, A. D., Adesina, S., Durodola, A., Amole, I., Singer, S., & Levine, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1006095 · Cited by 10 · see citing works
“Israel had encountered problem of access to EM in the past (41).”
BackgroundCommunity Pharmacy Staff Knowledge, Opinion and Practice toward Drug Shortages in Saudi Arabia
Alsheikh, M., Alzahrani, M. A., Alsharif, N. A., Altowairqi, H. M., Asiri, S., Althubaiti, B. M., Alshahrani, A., Fathelrahman, A., Alasmari, M. M., & Alotaibi, A. F. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.09.001 · Cited by 10 · see citing works
“…in many countries irrespective of the economic status (Lynas, 2010; Becker et al., 2013; Gupta and Huang, 2013; Jagsi et al., 2014; Caulder et al., 2015; de Weerdt et al., 2015a; de Weerdt et al., 2015b; Rosa et al., 2016; de Weerdt et al., 2017; Schwartzberg et al., 2017; Vanegas et al, 2019).”
Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
Altabas, V., Orlović, Z., & Baretić, M. (2025) · Diabetology · doi:10.3390/diabetology6060052 · Cited by 10 · see citing works
Roth, K., Darwish, C. C., Keller, M. D., Hammer, B. M., Ahmed-Winston, S., Escalante, E., Madrigal, V., Patrick, D., Diab, Y. A., Grant, C., et al. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.30871 · Cited by 7
Pelissari, R., Benamor, S., & de Oliveira, M. C. (2019) · Pharmaceutical Supply Chains - Medicines Shortages · doi:10.1007/978-3-030-15398-4_17 · Cited by 7
Innovation and The Israel Journal of Health Policy Research
Rosen, B., Israeli, A., & Schoenbaum, S. (2019) · Israel Journal of Health Policy Research · doi:10.1186/s13584-019-0353-1 · Cited by 5
“And, in 2017, the IJHPR published an article from a group based at the Ministry of Health about how Israel is addressing the challenge of drug shortages – an issue relevant to many countries around the world [15].”
BackgroundTruong, P., Rothe, C. C., & Bochenek, T. (2019) · Pharmaceutical Supply Chains - Medicines Shortages · doi:10.1007/978-3-030-15398-4_3 · Cited by 5
Schleipman, A. R., & Todorova, I. (2020) · Narrative Inquiry in Bioethics · doi:10.1353/nib.2020.0012 · Cited by 4
Yi, Q., Yang, N., Zeng, L., Huang, L., Zou, K., Chen, J.-J., Luo, J., Zhang, M., Diao, S., Yu, Q., et al. (2026) · BMC Public Health · doi:10.1186/s12889-026-26834-2 · Cited by 3 · see citing works
“Upon confirmation of a shortage, facilities are required to conduct an immediate stock assessment, estimating coverage duration to guide allocation decisions [21, 23, 30, 55].”
Uahupirapi, K., Shifotoka, S., & Nangombe, V. (2025) · Tropical Medicine and Health · doi:10.1186/s41182-025-00799-1 · Cited by 3 · see citing works
“These findings resemble those from Finland and Israel, where small markets faced similar vulnerabilities [57, 58].”
Drug shortages in Israel, revisited: a bitter pill to swallow
Schwartzberg, E., Marom, E., Vishkautzan, A., Gorelik, E., & Shani, S. (2024) · Israel Journal of Health Policy Research · doi:10.1186/s13584-024-00600-4 · Cited by 3
“In our previous article published in 2017 [8], we under-scored the emerging issue of drug shortages (DS) in Israel, a fact substantiated by the numerous instances observed between 2013 and 2017.”
ResultSelf-citationUpdates and reflections about the IJHPR, on the eve of its seventh year
Rosen, B., & Israeli, A. (2017) · Israel Journal of Health Policy Research · doi:10.1186/s13584-017-0196-6 · Cited by 2
“The topics covered include: reducing the burden of STI infections [13], Israel’s pediatric dental care reform [14], strategies for reducing health inequalities [15], tobacco control policy [10], educating the future Israeli medical workforce [16], drug shortages [17], medically-assisted reproduction [18], and vaccine…”
BackgroundTrends in Medicines Discontinuation and Implications for Access in Brazil (2014–2024)
de Lima, R. O. M., Silva, E. R., Emmerick, I., Santos, D. M. D. S. S. D., Godói, I. P. D., Campos, A. C., & Chaves, L. A. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70458 · Cited by 1
“Israel requires advance notification of possible shortages by marketing authorization holders, has established mandatory minimum stocks, and accelerated drug registration pathways to ensure alternatives in case of shortages [7].”
Tackling Drug Shortages: An In-Depth Systematic Review Protocol
Kanan, M., Alraya, R., Aljabri, A. K., Alsaadi, B. H., Althubyani, M. M., Alamri, S. H., Alqarni, A., Alenazi, Y., Almutairi, A., Alshehri, A., et al. (2025) · Pharmacy in practice · doi:10.18549/pharmpract.2025.2.3176 · Cited by 1 · see citing works
“In general, the reasons behind drug shortages can be attributed to problems with the drug supply, demand, or regulatory factors 20,21 .”
When I use a word . . . Managing pharmaceutical stocks stocklessly
Aronson, J. (2025) · British medical journal · doi:10.1136/bmj.r1229 · Cited by 1
Factors Affecting Drug Shortage in Aseer Hospitals
Assiry, A., Assiri, N., Asiri, I. M., Alnami, Y., Asiri, A. M., Alshehri, A. M., Almohammadi, A. F., Alkhurmani, H., & Alzhrani, A. (2023) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v3-i8-46 · Cited by 1
Drug Shortages and Its Effects on Service Delivery among Key Informants (KIs) in Fiji
Raikabakaba, A., Mohammadnezhad, M., Tamani, L., & Gaundan, D. (2022) · Global Journal of Health Science · doi:10.5539/gjhs.v14n5p1 · Cited by 2 · see citing works
“In Israel, based on the data collected by Ministry of Health, between 2013 and 2015 shows that total of 677 drug shortages notification were received (Schwartzberg et al., 2017).”
BackgroundPharmaceutical regulatory requirements of nonregulated markets
Ganesh, G., & Mohankumar, S. (2022) · Regulatory Affairs in the Pharmaceutical Industry · doi:10.1016/b978-0-12-822211-9.00002-2 · Cited by 1
Li, J.-J. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1587028
Nascimento, M. D. S., Grima, J. V. F., Araújo, K., & Santos, A. D. F. (2025) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv17n1-050
Strategies for addressing the shortage of medicines to improve service delivery
Modutlwa, N. (2024) · International Journal of Innovation in Management Economics and Social Sciences · doi:10.59615/ijimes.4.3.19 · Cited by 1 · see citing works
“The literature supports the results as collaboration is reported as a recommended strategy [16, 17, 18].”
Resolving shortages of prescription drugs: the case for public-private collaboration
Katz, E. (2017) · Israel Journal of Health Policy Research · doi:10.1186/s13584-017-0152-5
Towards a Basis for Policy Framework for Stockouts and Shortages of Drugs
Calucin, A. C. (2023) · International Conference on Industrial Engineering and Operations Management (IEOM) · doi:10.46254/an12.20220352
“A "drug shortage" is a scenario in which the overall supply of all clinically interchangeable variants of an FDA-regulated drug product is insufficient to satisfy expected demand at the user level" (Schwartzberg et al., 2017).”
Background
- Authors
- Schwartzberg, E., Ainbinder, D., Vishkauzan, A., & Gamzu, R.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Israel Ministry of Health (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Corresponding author
- Schwartzberg, Eyal
- Venue
- Israel Journal of Health Policy Research
- Published
- 2017-04-03
- Volume
- 6
- Issue
- 1
- Pages
- 17-17
- ISSN
- 2045-4015 (ISSN-L)
- PMC
- PMC5376685
- OpenAlex
- W2597963728
- Cited by
- 46
- References
- 18
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 7 · 2017: 3
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Israel Journal of Health Policy Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Teva Pharmaceutical Industries
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Health Professions › Health Information Management › Healthcare Regulation
- Keywords
- drug shortages, drug regulation, Israel, marketing authorization holders, generic drugs, raw material quality, just-in-time inventory
- MeSH terms
- Drug Industry, Health Resources, Humans, Israel, Public Health, Prescription Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
